There continues to be debate about optimal eating times and patterns for weight management and glycemic control in people with T2D. Intermittent fasting or early time-restricted eating (eTRE) has succeeded in clinical trials and gained popularity. The impact of a 72 - hour induction fast is a novel approach to amplify the benefits of eTRE in type 2 diabetes.The aim of this study is to determine the effects of 72 - hour induction fast on T2D patients undergoing 3 months of eTRE.In this single cohort experimental study, participants were randomized into either an initial 72 - hour induction fast group or a non-induction fast group. Both groups underwent an 8 - hour feeding window (8 AM to 4 PM) and a 16 - hour fasting window daily for 3 months.Participants were recruited from a network of healthcare centers of FQHC and were required to have a T2D diagnosis and diabetes medication therapy. A total of 17 participants enrolled with 11 completing the study. Key exclusion criteria included recent AKI or DKA. At baseline and 12 - weeks blood draws were performed to analyze glycemic and lipid profiles, and anthropometrics, number of medications, and blood pressure were measured.Paired t-tests showed there were no significant differences in results between the two groups. Induction Fast + eTRE group (n = 4), the pre - and post - data mean, respectively were A1c (7.9% vs 7.7%, p = 0.7), weight (265 vs 259 lbs., p = 0.09), BMI (37.8 vs 37.1, p = 0.12), & systolic bp (123 vs 112 mmHg, p = 0.05). For the non-Induction Fast + eTRE group (n = 7), the pre- and post-data mean, respectively were A1c (7.6% vs 7.7%, p = 0.69), weight (231 vs 227 lbs., p = 0.01), BMI (36 vs 33, p = 0.03), & systolic bp (122 vs 118, p = 0.46).This pilot study demonstrates that a 72 - hour Induction Fast resulted in a significant reduction in blood pressure whereas eTRE alone showed significant reductions in weight and BMI. Further planned analysis of blood chemistries may illustrate the additional benefits of a 72 - hour Induction Fast on eTRE.
A. Nijjar: None. K. Shaikh: None. T.L. Calinawan: None. I. Maldonado: None. G. Jones: None. J.H. Shubrook: Consultant; Abbott Diagnostics. Advisory Panel; Bayer Inc., Eli Lilly and Company, Madrigal Pharmaceuticals, Inc., Nevro Corp. Consultant; Novo Nordisk, Sanofi.